Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-21 · accession 0001367644-24-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-21 | EBS | LINDAHL RICHARD S | EVP, CFO | D - Sale to Iss | $2.71 | -4,012 | 169.0K | -2% | -$10.9K | |
| 2024-02-27 | 2024-02-23 | EBS | LINDAHL RICHARD S | EVP, CFO | F - Tax | $2.74 | -517 | 168.5K | -0.3% | -$1,417 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-21 | D | D | 4,012 | $2.71 | 168,980 | D | — | — | (F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. On February 21, 2024, the final certification date, the Compensation Committee certified the achievement of the 2021-2023 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 4,012 shares previously reported on February 24, 2021. |
| 2 | Common | Common Stock | 2024-02-23 | F | D | 517 | $2.74 | 168,463 | D | — | — | (F2) Represents shares of common stock withheld to pay taxes. |